| Project/Area Number |
23591512
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
MINAMI KOICHI 和歌山県立医科大学, 医学部, 講師 (60301438)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Hiroyuki 和歌山県立医科大学, 医学部, 准教授 (80196865)
YOSHIKAWA Norishige 和歌山県立医科大学, 医学部, 教授 (10158412)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 溶血性尿毒症症候群 / 急性脳症 / グリア細胞 / ケモカイン / Cannabinoids / 志賀毒素 |
|---|
| Research Abstract |
Infection with Shiga toxin (Stx)-producing Escherichia coli can lead to development of hemolytic uremic syndrome (HUS). Approximately 30% of patients with HUS suffer from central nervous system (CNS) complications and these patients have the poorest prognosis. It has been suggested that vascular endothelial injuries caused by Stxs play a crucial role in the development of the disease. Furthermore, the relationship of glial cell damage and Stxs is considered.
In this study, we investigated chemokine suppression mechanism using Cannabinoids in human astrocyte, and aimed to confirm the effect of disease specific therapy development based on the pathophysiology of HUS encephalopathy.
|
